✦ LIBER ✦

The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas

✍ Scribed by G. S. Liem; J. Verweij

Book ID: 112212639
Publisher: AlphaMed Press
Year: 1994
Tongue: English
Weight: 590 KB
Volume: 12
Category: Article
ISSN: 1066-5099
DOI: 10.1002/stem.5530120407

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Should high-dose chemotherapy be used in

Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?: Arbiter

✍ D. Crowther 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 318 KB

Should high-dose chemotherapy be used in

Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?: Contra

✍ J. Verweij 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 890 KB

Should high-dose chemotherapy be used in

Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?: Pro

✍ P. Reichardt 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 554 KB

Granulocyte colony stimulating factor pe

Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children

✍ R.B Womer; R.T Daller; J.Gallagher Fenton; J.S Miser 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 195 KB

The reason for confining the use of adju

The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting

✍ Jaap Verweij; Caroline Seynaeve 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 743 KB

Dose-intensive chemotherapy with growth

Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma : A systematic review

✍ Shailendra Verma; Jawaid Younus; Denise Stys-Norman; Adam E. Haynes; Martin Blac 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

## Abstract A systematic review was performed to determine whether first‐line dose‐intensive chemotherapy supported by growth factor or autologous bone marrow/stem cell transplantation improves response rate, time‐to‐disease progression, or survival compared with standard‐dose chemotherapy in patie